No human trial has shown that fasting shrinks or eliminates existing arterial plaque. The honest state of the evidence is that fasting triggers several biological processes that look promising on paper, including reduced inflammation, improved lipid profiles, and protection of blood vessel walls, but the leap from those changes to actual plaque reversal in living people remains unproven. Animal studies have shown reduced plaque buildup with time-restricted feeding, and fasting clearly improves many of the risk factors that drive atherosclerosis forward. Whether that adds up to reversal, stabilization, or simply slower progression is a question the science has not yet settled.
Why Atherosclerosis Is So Hard to Undo
Atherosclerosis is not simply cholesterol stuck to an artery wall. It is a decades-long process involving inflammation, immune cell infiltration, cell death, scar tissue formation, and eventually calcification. Fatty streaks appear in arteries as early as childhood. Over time, lipids accumulate in the artery wall, immune cells called macrophages swallow them and die, and a necrotic core forms beneath a fibrous cap. The dangerous moment comes when that cap thins enough to rupture, exposing the inner material to blood and triggering a clot that can cause a heart attack or stroke.
The complexity of this progression is what makes reversal so difficult. You are not dealing with a simple deposit that can be dissolved. A mature plaque contains calcium, dense scar tissue, dead cells, and crystallized cholesterol. Even potent statin therapy, which can dramatically lower LDL cholesterol, typically achieves only modest plaque volume reduction after years of treatment. So the bar for any intervention claiming to “reverse” atherosclerosis is high. Fasting research, while genuinely exciting in certain mechanistic areas, has to be evaluated against this reality.
How Fasting Dampens Arterial Inflammation
One of the strongest lines of evidence connecting fasting to cardiovascular benefit involves the NLRP3 inflammasome, a molecular complex inside immune cells that drives the kind of chronic, low-grade inflammation central to plaque growth. When NLRP3 activates, it triggers the release of inflammatory signaling molecules that attract more immune cells to the artery wall, accelerating damage. Emerging evidence, mostly from cell and animal experiments, shows that the ketone body beta-hydroxybutyrate, which rises sharply during fasting, reduces NLRP3 activation and improves chronic inflammation.1PubMed Central. Impact of fasting & ketogenic interventions on the NLRP3 inflammasome: A narrative review
Mouse studies have drilled into the mechanism further. In one set of experiments, prolonged fasting blunted NLRP3 inflammasome activity in normal mice but failed to do so in mice lacking a specific protein called SIRT3, which is involved in mitochondrial health. Without SIRT3, immune cells pumped out more reactive oxygen species and leaked mitochondrial DNA into the cell body, both of which keep the inflammasome firing.2Journal of Biological Chemistry. Fasting and SIRT3 control NLRP3 inflammasome activation by suppressing mitochondrial ROS A separate human study found that plasma levels of arachidonic acid rise during fasting and that this fatty acid directly inhibits NLRP3-driven inflammation in immune cells, including inflammation triggered by lipids, the very type relevant to plaque growth.3Cell Reports. Arachidonic acid inhibits the NLRP3 inflammasome and explains the anti-inflammatory effects of fasting
These findings matter because inflammation is not just a side effect of atherosclerosis; it is a driver. The drugs that have proven most effective at preventing cardiovascular events, statins and the newer anti-inflammatory antibody canakinumab, work in part by reducing inflammatory signaling. If fasting can reliably suppress the same pathways, it could at least slow plaque progression. But “suppressing a pathway in a cell dish” and “shrinking a calcified plaque in a human coronary artery” are very different achievements.
What Happens to Lipids When You Fast
Fasting reshapes your blood lipid profile in ways that are mostly, but not entirely, favorable. A study of two-week continuous fasting in humans found significant drops in cholesterol carried by all three LDL subfractions, along with a meaningful reduction in total LDL particle count after 14 days.4PubMed Central. Long-term fasting improves lipoprotein-associated atherogenic risk in humans Since LDL particle number is among the strongest predictors of atherosclerotic risk, these changes look protective. Fasting regimens more broadly are associated with lower blood triglycerides, total cholesterol, and triglyceride-rich particles including VLDL.5Journal of Lipid Research. Effects of fasting on HDL particle function and size distribution
HDL function also appears to improve. The capacity of HDL particles to pull cholesterol out of cells, a process called cholesterol efflux, has been shown to increase following fasting interventions.5Journal of Lipid Research. Effects of fasting on HDL particle function and size distribution This is relevant because cholesterol efflux from macrophages in the artery wall is one of the few established mechanisms through which plaques could theoretically shrink. If HDL particles become better at their job during fasting, you have a plausible route from fasting to plaque regression, at least in principle.
The picture is not uniformly positive, though. A randomized trial comparing alternate-day fasting to standard calorie restriction over 12 months found that LDL cholesterol actually rose in the fasting group relative to the calorie-restriction group by about 11.5 mg/dL, and the temporary HDL boost seen at six months had disappeared by the end of the study.6JAMA Internal Medicine. Effect of Alternate-Day Fasting on Weight Loss, Weight Maintenance, and Cardioprotection Among Metabolically Healthy Obese Adults: A Randomized Clinical Trial The study found no significant differences in blood pressure, triglycerides, fasting glucose, insulin resistance, or C-reactive protein between the two groups. That result is sobering: when compared head-to-head with ordinary calorie restriction, alternate-day fasting did not deliver a clear cardiovascular advantage in metabolically healthy obese adults and may have worsened one key risk marker.
Ketone Bodies and Blood Vessel Protection
Beyond suppressing inflammation, the ketone body beta-hydroxybutyrate appears to protect blood vessels more directly. A review in a major cardiology journal noted that exogenous ketone bodies have been shown to increase coronary blood flow, promote endothelial function and new blood vessel growth, increase muscle oxygenation, and inhibit atherosclerosis, vascular calcification, and cellular senescence.7PubMed Central. Ketone Bodies in Cardiovascular Disease: The Vasculature as a Therapeutic Target That is a striking list, but much of it comes from animal and cell studies rather than human clinical endpoints.
In diabetic rats, beta-hydroxybutyrate treatment reduced damage to the aortic lining and promoted production of a growth factor involved in blood vessel repair. The protective effect was strongest at moderate concentrations of the ketone body, suggesting a dose-dependent sweet spot rather than a “more is better” relationship.8PubMed. β-hydroxybutyrate antagonizes aortic endothelial injury by promoting generation of VEGF in diabetic rats Separately, when human endothelial cells were exposed to inflammatory conditions, beta-hydroxybutyrate significantly reduced the production of damaging superoxide molecules inside mitochondria while boosting antioxidant gene activity and overall mitochondrial function.9PubMed Central. Effect of Ketone Body β-Hydroxybutyrate to Attenuate Inflammation-Induced Mitochondrial Oxidative Stress in Vascular Endothelial Cells
There is also intriguing work on cellular aging. When mice fasted for 72 hours, beta-hydroxybutyrate levels in their blood roughly quadrupled, and markers of youthful cell state rose dramatically in their aortic tissue. In mouse aortic roots that had developed atherosclerosis, the areas showing signs of cell senescence did not overlap with areas expressing the protective factor Oct4, suggesting that chronically elevated beta-hydroxybutyrate could reduce or delay the aging of vascular cells.10Cell Press (Molecular Cell). β-Hydroxybutyrate Prevents Vascular Senescence through a Quiescence-Mediated Pathway Senescent cells in plaques are a known contributor to instability and rupture risk, so slowing their accumulation could theoretically make existing plaques safer even if they don’t shrink.
Animal Evidence for Plaque Reduction
The most direct evidence that fasting can affect plaque comes from mouse models. In mice whose circadian rhythms were deliberately disrupted (a model that accelerates atherosclerosis and mirrors the cardiovascular risks of shift work), time-restricted feeding reduced the area of atherosclerotic lesions. The intervention fully prevented the increase in macrophage content within lesions that circadian disruption would otherwise cause, without dramatically altering overall lesion severity or collagen content.11The Lancet. Time-restricted feeding attenuates atherosclerosis development in circadian disturbed mice
This is genuinely encouraging but needs context. These mice were genetically prone to atherosclerosis and were being actively harmed by circadian disruption. Time-restricted feeding attenuated the development of new plaque; it did not demonstrate shrinkage of established plaque. In animal research, preventing a disease from progressing and reversing damage already done are distinct outcomes, and most fasting studies in animals have measured the former. The translation from mouse arteries to human coronary disease is also notoriously unreliable. Mouse plaques develop in weeks and rarely calcify the way human plaques do over decades.
What We Know From Humans So Far
Human evidence for fasting’s effect on actual arterial structure is thin. The closest surrogate measure commonly used is carotid intima-media thickness, the combined thickness of the inner two layers of the carotid artery wall. Higher IMT correlates with more atherosclerosis and greater cardiovascular risk. One study in women found that IMT increased with rising fasting blood glucose levels, particularly when glucose was below 7 mmol/L, and that postmenopausal women had thicker readings than premenopausal women.12PubMed Central. Effect of fasting glucose levels on carotid intima-media thickness in premenopausal versus postmenopausal women This tells us that fasting glucose, one of the metabolic parameters fasting interventions can improve, tracks with arterial thickening. It does not tell us that fasting itself reverses that thickening.
Where human data is more encouraging is in endothelial function, the ability of your artery walls to relax and dilate properly. A study of overweight and obese individuals found that fasting therapy improved flow-mediated dilation, a standard test of endothelial health, from about 5.3% to 6.3%. The improvement was linked to activation of autophagy in endothelial progenitor cells, the stem-cell-like cells that repair blood vessel linings.13PubMed Central. Fasting Therapy Contributes to the Improvement of Endothelial Function and Decline in Vascular Injury-Related Markers in Overweight and Obese Individuals via Activating Autophagy of Endothelial Progenitor Cells Endothelial dysfunction is one of the earliest events in atherosclerosis, so improving it is relevant, but this is still upstream of plaque regression.
No published trial has used coronary CT angiography, intravascular ultrasound, or any direct imaging technique to show that a fasting protocol shrank human coronary plaques. Until that kind of evidence exists, claims about fasting “reversing” atherosclerosis remain speculative extrapolations from mechanism and risk-factor data.
Which Fasting Protocols Show the Most Cardiovascular Promise
Not all fasting schedules appear to deliver the same cardiovascular benefits. A recent systematic review and network meta-analysis compared several intermittent fasting protocols against normal eating for cardiovascular risk factors. Modified alternate-day fasting, where you eat roughly 25% of normal calories on fasting days rather than nothing at all, performed best for reducing body weight (about 5 kg more than usual diet), waist circumference, and both systolic and diastolic blood pressure. Time-restricted eating, typically an eating window of 8 hours or fewer, was most effective for reducing fasting blood glucose and also meaningfully lowered waist circumference and diastolic blood pressure.14PubMed Central. Intermittent Fasting for the Prevention of Cardiovascular Disease Risks: Systematic Review and Network Meta-Analysis
These are risk-factor improvements, not direct evidence of plaque changes, but they are the kind of improvements that decades of cardiovascular research have shown to matter. Lower blood pressure, smaller waist circumference, and better blood sugar control each independently reduce atherosclerotic risk. Animal evidence also suggests that aligning eating with circadian rhythms, eating during the active phase and fasting during the rest phase, may be part of why time-restricted feeding protects blood vessels.15Science Bulletin. Intermittent fasting and cardiovascular health: a circadian rhythm-based approach That finding is consistent with the mouse study showing that time-restricted feeding counteracted the cardiovascular damage of circadian disruption.
The practical takeaway is that fasting protocols with moderate calorie restriction on fasting days and those that respect circadian biology by limiting late-night eating show the most consistent cardiovascular benefit in meta-analyses. Extreme prolonged fasts do not have this level of systematic support, and their risks are considerably higher.
Risks That Could Undermine Cardiovascular Goals
Fasting is not risk-free, and some of the risks directly conflict with cardiovascular health goals. As noted in the JAMA Internal Medicine trial, alternate-day fasting raised LDL cholesterol relative to standard dieting over 12 months.6JAMA Internal Medicine. Effect of Alternate-Day Fasting on Weight Loss, Weight Maintenance, and Cardioprotection Among Metabolically Healthy Obese Adults: A Randomized Clinical Trial This is a real concern, because LDL is the single strongest modifiable driver of atherosclerosis. A person who fasts hoping to protect their arteries but ends up with higher LDL may be doing net harm.
There are also extreme case reports that illustrate the dangers of prolonged fasting in people with existing heart disease. One patient with symptomatic multivessel coronary artery disease and heart failure underwent 50 days of continuous fasting. He experienced severe dehydration and electrolyte abnormalities requiring intravenous fluids and electrolyte replacement. Though his hemodynamics remained stable and he reported no chest pain, likely due to ketosis-mediated cardiac protection, this is not a model anyone should follow.16PubMed Central. First Report Of 50-Day Continuous Fasting in Symptomatic Multivessel Coronary Artery Disease and Heart Failure: Cardioprotection Through Natural Ketosis Electrolyte disturbances during fasting can trigger fatal cardiac arrhythmias, which is a particular risk for people whose hearts are already compromised.
A separate and underappreciated phenomenon involves the “lean mass hyper-responder” pattern. Some individuals, typically lean people on very low-carbohydrate or fasting-heavy regimens, experience dramatic spikes in LDL cholesterol. One published case report documented an individual whose LDL-C rose from 95 to 545 mg/dL on a carbohydrate-restricted diet, despite having HDL above 100 and very low triglycerides. Interestingly, a CT angiogram after more than two years of this extreme hypercholesterolemia showed no calcified or non-calcified plaque.17PubMed Central. Case Report: Hypercholesterolemia “Lean Mass Hyper-Responder” Phenotype Presents in the Context of a Low Saturated Fat Carbohydrate-Restricted Diet That single case is fascinating but cannot be generalized. Most cardiologists would consider an LDL of 545 extremely dangerous regardless of the accompanying lipid profile. People who adopt aggressive fasting protocols should monitor their lipids, not assume the intervention is automatically protective.
Tracking Whether Plaques Are Actually Changing
One reason the evidence for plaque reversal is so thin is that measuring plaque change is expensive and invasive. The gold standard is intravascular ultrasound, which threads a tiny probe inside a coronary artery. Less invasive options include coronary CT angiography and carotid ultrasound. Researchers studying plaque progression have identified plasma biomarkers that correlate with changes in carotid IMT, including inflammatory markers like C-reactive protein and IL-6, connective tissue growth factors, and markers of cell death. High levels of connective tissue growth factors in the blood were significantly associated with progression of carotid IMT even after adjusting for age, sex, smoking, and LDL cholesterol.18Cell Reports Medicine. Progression of carotid atherosclerosis is associated with novel plasma biomarkers and plaque characteristics
These biomarkers could eventually allow researchers to assess whether fasting interventions are actually remodeling plaques without requiring invasive imaging at every time point. Some of the markers that track with plaque progression, particularly inflammatory ones, are the same molecules that fasting appears to suppress. But tracking biomarker improvement and proving plaque regression are two different things. What the field needs, and does not yet have, is a randomized trial that assigns people with established atherosclerosis to a fasting protocol and measures plaque volume with direct imaging before and after. Until that study is done, the mechanistic case remains stronger than the clinical proof.
The Evolutionary Argument for Why Fasting Might Help
There is an interesting theoretical framework that helps explain why fasting could protect against atherosclerosis even if it cannot fully reverse it. The argument, laid out in a recent cardiology review, is that atherosclerosis is fundamentally a mismatch disease: our metabolic systems evolved under conditions of intermittent food scarcity and physical exertion, and the chronic, unrelenting activation of those same systems by modern diets and sedentary living is what drives arterial disease.19Current Problems in Cardiology. Atherosclerosis as an evolutionary mismatch disease: from ancestral biology to cardiometabolic vulnerability Human metabolism evolved to toggle between fed and fasted states, using stored fat during scarcity and replenishing glycogen and fat stores when food was available. The modern pattern of eating from morning to late at night with no fasting interval may keep inflammatory and metabolic pathways chronically active in ways they were never designed to handle.20PubMed Central. The sedentary (r)evolution: Have we lost our metabolic flexibility?
Under this framework, fasting does not work as a drug that targets atherosclerosis specifically. Instead, it restores a metabolic rhythm that our physiology expects. The anti-inflammatory effects, the improved lipid handling, the enhanced autophagy, and the ketone body signaling are not isolated pharmacological actions but rather normal features of a metabolism that periodically cycles through scarcity. If this framing is correct, the question shifts from “can fasting reverse atherosclerosis” to “can returning to ancestral metabolic patterns slow or prevent a disease driven by the absence of those patterns.” The latter question is more modest but possibly more realistic, and the accumulating evidence from risk-factor trials, animal models, and mechanistic studies leans cautiously in its favor.
The Role of Autophagy in Plaque Stability
One mechanism that deserves attention on its own is autophagy, the cellular recycling process that fasting is well known to activate. Inside atherosclerotic plaques, macrophages that have gorged on oxidized lipids become foam cells, and when those foam cells die, they release their contents into the growing necrotic core. Autophagy in macrophages has been linked to better lipid metabolism within these cells, reduced inflammatory signaling, and an overall suppression of processes that promote plaque growth.21PubMed Central. Self-eating in the plaque: what macrophage autophagy reveals about atherosclerosis When autophagy works well, macrophages handle cholesterol more efficiently and are less likely to die and dump their lipid cargo into the plaque.
The connection to fasting is logical but indirect. Fasting is one of the strongest natural triggers of autophagy, and defective autophagy in plaque macrophages is associated with larger necrotic cores and thinner fibrous caps, exactly the features that make a plaque rupture-prone.22PubMed. Mechanisms of plaque formation and rupture If fasting-induced autophagy could be shown to reach macrophages already embedded in plaques and improve their housekeeping, that would represent a plausible pathway to plaque stabilization. Stabilizing a plaque, making it less likely to rupture even without shrinking it, would be a clinically meaningful outcome. Whether fasting reliably achieves this in human arteries remains undemonstrated. The biology is consistent, but the clinical proof is not there yet.
Where the Gut Microbiome Fits In
An area of growing but still early research connects fasting to the gut microbiome and its influence on cardiovascular risk. Intermittent fasting alters the composition and metabolic output of gut bacteria, which in turn affects host metabolism. Emerging evidence suggests these microbial shifts may link to changes in insulin sensitivity, inflammation, and lipid metabolism, all of which feed into atherosclerotic risk.23PubMed Central. Time-limited diets and the gut microbiota in cardiometabolic disease Certain bacterial metabolites have been independently linked to cardiovascular events in large epidemiological studies, and if fasting shifts the microbial community toward producing fewer harmful metabolites, that would add another layer to its cardiovascular potential. But this line of research is still mostly hypothesis-generating. The causal chain from fasting to gut bacteria to plaque biology is plausible but several links remain unverified in humans.